Veradermics (MANE) CEO adds 234,872 shares and 556,399 options

Rhea-AI Filing Summary

Veradermics, Inc. Chief Executive Officer and director Reid Alexander Waldman reported insider equity changes. On February 5, 2026, 1,437 shares of Series A Convertible Preferred Stock automatically converted into 1,437 shares of common stock on a 10.067-for-1 basis, bringing his directly held common stock to 234,872 shares.

Separately, on February 3, 2026, he was granted a stock option for 556,399 shares of common stock at an exercise price of $17 per share. The option vests 25% on February 3, 2027, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued service.

Insider Trade Summary

1,437 shares exercised/converted

Mixed 3 txns

Insider Waldman Reid Alexander

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Conversion	Series A Convertible Preferred Stock	1,437	$0.00	--
Conversion	Common Stock	1,437	$0.00	--
Grant/Award	Stock Option (Right to Buy)	556,399	$0.00	--

Holdings After Transaction: Series A Convertible Preferred Stock — 0 shares (Direct); Common Stock — 234,872 shares (Direct); Stock Option (Right to Buy) — 556,399 shares (Direct)

Footnotes (1)

1. On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. The option vests as to 25% of the underlying shares of Common Stock on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waldman Reid Alexander

(Last) (First) (Middle)

C/O VERADERMICS, INCORPORATED

470 JAMES ST.

(Street)

NEW HAVEN CT 06513

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		C(1)		1,437	A	(1)	234,872	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Preferred Stock	(1)	02/05/2026		C			1,437	(1)	(1)	Common Stock	1,437	(1)	0	D
Stock Option (Right to Buy)	$17	02/03/2026		A		556,399		(2)	02/03/2036	Common Stock	556,399	$0	556,399	D

Explanation of Responses:

1. On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

2. The option vests as to 25% of the underlying shares of Common Stock on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.

Remarks:

	/s/ Michael Greco, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Veradermics (MANE) CEO Reid Alexander Waldman report?

Reid Alexander Waldman reported a preferred-to-common conversion and a new option grant. 1,437 Series A preferred shares converted into 1,437 common shares, and he received a stock option for 556,399 common shares at a $17 exercise price.

How many Veradermics (MANE) common shares does the CEO hold after these transactions?

After the reported transactions, the CEO directly holds 234,872 common shares. This figure reflects the automatic conversion of 1,437 Series A Convertible Preferred shares into 1,437 common shares on February 5, 2026, immediately before the company’s initial public offering closing.

What are the terms of the 556,399-share stock option granted to the Veradermics (MANE) CEO?

The CEO received a stock option for 556,399 common shares at a $17 exercise price. The option vests 25% on February 3, 2027, then in equal monthly installments over 36 months, conditioned on his continued service with Veradermics.

What happened to the Series A Convertible Preferred Stock held by the Veradermics (MANE) CEO?

All reported Series A Convertible Preferred Stock automatically converted into common shares. On February 5, 2026, 1,437 preferred shares converted into 1,437 common shares at a 10.067-for-1 ratio, with no additional consideration, just before the company’s initial public offering closing.

Is the Veradermics (MANE) CEO’s stock option grant tied to continued service?

Yes, the option grant is service-based. Twenty-five percent of the 556,399-share option vests on February 3, 2027, and the remaining shares vest in equal monthly installments over 36 months, all subject to the CEO’s continued service with the company.

Does the Form 4 show the Veradermics (MANE) CEO buying or selling shares on the market?

The Form 4 does not show open-market buys or sells. It reports an automatic conversion of preferred stock into common stock and a granted stock option award, both at a reported price of zero per share rather than market transactions.